Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Sifrol
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-086614 · Präparat HOS-083320
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with SIFROL.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T12:07:00Z · SHA-256 b4f30a08cef428369f4933c2b378c5c4863a47cff3160855eb93c9a7a44d185f · Passage 8e8090250373964867c33aa46943436e77528be4b79a8f09c2a60fb620560a97 · Zeichen 528–1178 im Abschnitt
Wechselwirkungen · Sifrol
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-086639 · Präparat HOS-083320
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with SIFROL.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T12:07:00Z · SHA-256 b4f30a08cef428369f4933c2b378c5c4863a47cff3160855eb93c9a7a44d185f · Passage 8e8090250373964867c33aa46943436e77528be4b79a8f09c2a60fb620560a97 · Zeichen 528–1178 im Abschnitt
Wechselwirkungen · Mirapexin
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-086658 · Präparat HOS-083333
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
MIRAPEXIN.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage c3d535d02c07dc607a17c04a61ed80b6fe9c1368f787d3518bc7b336caa51a8f · Zeichen 528–1181 im Abschnitt
Wechselwirkungen · Mirapexin
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-086680 · Präparat HOS-083333
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
MIRAPEXIN.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage c3d535d02c07dc607a17c04a61ed80b6fe9c1368f787d3518bc7b336caa51a8f · Zeichen 528–1181 im Abschnitt
Wechselwirkungen · Pramipexole Teva
Pramipexole Teva 0.088 mg tablets Pramipexole Teva 0.18 mg tablets Pramipexole Teva 0.35 mg tablets Pramipexole Teva 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119859 · Präparat HOS-095037
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34 %, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
Pramipexole Teva.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-02T17:36:00Z · SHA-256 5d166932f43f2c779defb4b949fcb54f71a25cc3c96586af3caa034b7968230d · Passage 9612017193804eaed13008b81d23b6818915877f495ddeb3c0feb065e277c878 · Zeichen 529–1189 im Abschnitt
Wechselwirkungen · Oprymea
Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119883 · Präparat HOS-095045
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine,amantadine mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact with
pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose should
be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage 2fdce5dc531858bbce43c87a98e2962959fe2618a603b974e30acb20dea40533 · Zeichen 527–1176 im Abschnitt
Wechselwirkungen · Oprymea
Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets Oprymea 1.57 mg prolonged-release tablets Oprymea 2.1 mg prolonged-release tablets Oprymea 2.62 mg prolonged-release tablets Oprymea 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-119906 · Präparat HOS-095045
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage a81b331c51d21971ec198f1baf2e2b7c7f649d675f0c36d1d3422ffb4447ae79 · Zeichen 527–1178 im Abschnitt
Wechselwirkungen · Oprymea
Treatment initiation pack Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 33–34
HOS-119927 · Präparat HOS-095045
33
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage 310b41eb637c07db4e7b10aeb2c74f8b22c2661ab8b99d1af6d9f9f8b5d59d99 · Zeichen 637–1233 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.